Zacks Research Weighs in on Halozyme Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Zacks Research boosted their Q3 2025 EPS estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of $1.01 per share for the quarter, up from their prior estimate of $0.98. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.45 per share. Zacks Research also issued estimates for Halozyme Therapeutics' FY2025 earnings at $3.92 EPS and Q1 2026 earnings at $1.21 EPS.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million.

A number of other analysts also recently issued reports on the stock. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They set an "outperform" rating and a $54.00 price objective for the company. JMP Securities reissued a "market outperform" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. Benchmark reissued a "buy" rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. The Goldman Sachs Group lowered their price target on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating for the company in a research note on Thursday, January 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, April 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $53.29.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO traded up $0.26 during mid-day trading on Tuesday, reaching $38.97. 557,947 shares of the company were exchanged, compared to its average volume of 1,252,820. Halozyme Therapeutics has a 52 week low of $29.85 and a 52 week high of $45.00. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The stock has a market capitalization of $4.95 billion, a PE ratio of 18.48, a PEG ratio of 0.45 and a beta of 1.25. The company's 50 day moving average price is $39.62 and its 200 day moving average price is $37.78.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of HALO. TD Asset Management Inc increased its position in shares of Halozyme Therapeutics by 517.0% during the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company's stock valued at $73,326,000 after buying an additional 1,662,390 shares during the period. Norges Bank bought a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $44,935,000. Epoch Investment Partners Inc. increased its stake in shares of Halozyme Therapeutics by 250.5% during the fourth quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company's stock valued at $42,986,000 after purchasing an additional 831,199 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Halozyme Therapeutics by 174.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company's stock valued at $33,894,000 after purchasing an additional 563,989 shares in the last quarter. Finally, Boston Partners increased its stake in shares of Halozyme Therapeutics by 562.2% during the fourth quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company's stock valued at $20,218,000 after purchasing an additional 468,977 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company's stock, valued at $6,519,075.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 30,000 shares of company stock valued at $1,196,800. Insiders own 2.70% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.